Compare ResMed Inc. (RMD) vs Smurfit WestRock plc Ordinary Shares (SW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Smurfit WestRock plc Ordinary Shares — how do they compare? ResMed Inc. trades at $227.51 (market cap $31.78B), while Smurfit WestRock plc Ordinary Shares trades at $41.51 (market cap $21.66B). The key difference: ResMed Inc. is the larger of the two by market cap, and Smurfit WestRock plc Ordinary Shares pays the higher dividend (4.38%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Smurfit WestRock plc Ordinary Shares for 0 Days on average.
| RMD | SW | |
|---|---|---|
Market Cap | $31.78B | $21.66B |
Volume | 1,128,382 | 3,627,328 |
Sector | Health | Consumer Cyclical |
52-Week High | $277.88 | $51.84 |
52-Week Low | $182.82 | $32.79 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $31.14B | $35.14B |
Dividend Yield | 1.17% | 4.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →
